Source-grounded facts extracted from Aclaris Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Aclaris Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Aclaris Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2026-06-04 meeting.
“The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.”
Aclaris Therapeutics, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-04 meeting.
“The stockholders elected two nominees to serve as directors on the Board of Directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified.”
Aclaris Therapeutics, Inc. reported first quarter of 2026 results: revenue $2.0 million, net income Net loss was $19.8 million.
“First quarter 2026 Net loss was $19.8 million for the first quarter of 2026 compared to $15.1 million for the first quarter of 2025. Total revenue was $2.0 million for the first quarter of 2026 compared to $1.5 million for the first quarter of 2025.”
Aclaris Therapeutics, Inc.: Increased authorized common stock from 200,000,000 to 400,000,000 shares (effective 2025-06-05).
“the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 shares to 400,000,000 shares”
Neal Walker changed role as President at Aclaris Therapeutics, Inc..
“In connection with Dr. Davis’s appointment, Neal Walker will no longer serve as the Company’s President but will continue to serve as the Company’s Interim Chief Executive Officer.”
Hugh Davis was appointed as Class III Director at Aclaris Therapeutics, Inc..
“The Board also appointed Dr. Davis to the Board, effective November 18, 2024, to serve as a Class III director”
Hugh Davis was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..
“On November 16, 2024, the board of directors (the “ Board ”) of the Company appointed Hugh Davis, Ph.D., as the Company’s President and Chief Operating Officer effective November 18, 2024.”
Aclaris Therapeutics, Inc. reported first quarter of 2024 results: revenue $2.4 million, net income Net loss was $16.9 million.
“ Financial Results First Quarter 2024 ● Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023. ● Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023. The decrease was primarily driven by lower contract research revenue during the three months”
Bryan Reasons departed as Director at Aclaris Therapeutics, Inc..
“Also on March 14, 2024, Bryan Reasons, a member of the Board, notified the Company that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Annual Meeting.”
Andrew Powell resigned as Director at Aclaris Therapeutics, Inc..
“On March 14, 2024, Andrew Powell, a member of the board of directors (the “ Board ”) of Aclaris Therapeutics, Inc. (the “ Company ”), notified the Company of his intent to resign as a member of the Board, effective as of the date of the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 6, 2024 (the “ Annual Meeting ”).”
Aclaris Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022., net income Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N.
“Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2023”
Douglas Manion departed as Chief Executive Officer and President at Aclaris Therapeutics, Inc..
“On February 4, 2024, in connection with Douglas Manion’s departure from the Company as the Company’s Chief Executive Officer and President, the Company and Dr. Manion entered into a Separation Agreement”
Gail Cawkwell was terminated as Chief Medical Officer at Aclaris Therapeutics, Inc..
“On January 31, 2024, Aclaris Therapeutics, Inc. (the “ Company ”) terminated the employment of Gail Cawkwell, M.D., PhD., the Company's Chief Medical Officer, without cause, effective immediately.”
Neal Walker was appointed as Interim Chief Executive Officer and President at Aclaris Therapeutics, Inc..
“in connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024.”
Douglas Manion resigned as Chief Executive Officer and President at Aclaris Therapeutics, Inc..
“On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “ Board ”), effective January 16, 2024.”
Neal Walker was appointed as Interim Chief Executive Officer and President at Aclaris Therapeutics, Inc..
“the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024.”
Douglas Manion resigned as Chief Executive Officer and President at Aclaris Therapeutics, Inc..
“On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “ Board ”), effective January 16, 2024.”
Aclaris Therapeutics, Inc. announced a restructuring with charges of totaling approximately $3.1 million (approximately 46%).
“order to streamline operations, reduce costs and preserve capital. As a result of the reduction in force, the Company expects to incur a one-time charge totaling approximately $3.1 million in connection with one-time employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending December 31,”
Aclaris Therapeutics, Inc. reported third quarter of 2023 results: revenue $9.3 million, net income net loss was $29.3 million.
“Results Third Quarter 2023 ● Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022. ● Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022. The decrease was primarily driven by a one-time upfront payment under the non- ”
Joseph Monahan changed role as Chief Scientific Officer at Aclaris Therapeutics, Inc..
“Dr. Monahan will continue to serve as the Company’s Chief Scientific Officer but will shift to part-time status, pursuant to which he will provide services at 60% of a full-time schedule.”
Aclaris Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
“Proposal No. 4 : Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Aclaris Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares at the 2023-06-01 meeting.
“Proposal No. 3 : Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares .”
Aclaris Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2023-06-01 meeting.
“Proposal No. 2 : Advisory approval of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.”
Aclaris Therapeutics, Inc. shareholders approved Election of three nominees to serve as directors at the 2023-06-01 meeting.
“Proposal No. 1 : Election of three nominees to serve as directors on the Board of Directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified.”
Aclaris Therapeutics, Inc. entered into Office Lease with CBCC – Lee Road Acquisitions, LLC valued at Base rent initial $30,114.58 per month after abatement, term from November 1, 2023 to March 31, 2029 (effective 2023-05-26).
“On May 26, 2023, Aclaris Therapeutics, Inc. (the “ Company ”) entered into an Office Lease (the “ Lease ”) with CBCC – Lee Road Acquisitions, LLC, a Delaware limited liability company (the “ Landlord ”), under which the Company will lease 11,564 square feet of space for its corporate headquarters to be located at 701 Lee Road, Wayne, Pennsylvania 19087. The term of the Lease is anticipated to commence on November 1, 2023 and expire on March 31, 2029. Under the Lease, base rent for the first four months of the term shall be abated, after which the Company will pay an initial base rent of $30,114.58 per month for the following eight months. Beginning on the 13th month of the Lease, the monthly base rent will increase annually as specified in the Lease. In addition, the Company will pay its pro rata share of the annual operating expenses and taxes associated with the premises, calculated as set forth in the Lease. The Company has the option to extend the initial term for an additional fi”
Aclaris Therapeutics, Inc. reported the first quarter of 2023 results: revenue $2.5 million, net income Net loss was $28.2 million.
“ Financial Results First Quarter 2023 ● Net loss was $28.2 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022. ● Total revenue was $2.5 million for the first quarter of 2023 compared to $1.5 million for the first quarter of 2022. The increase was driven primarily by higher licensing revenues from royalties earned on”
Kevin Balthaser was appointed as Chief Financial Officer at Aclaris Therapeutics, Inc..
“appointed Kevin Balthaser as the Company’s Chief Financial Officer, effective as of January 1, 2023.”
Douglas Manion was appointed as Chief Executive Officer at Aclaris Therapeutics, Inc..
“appointed Douglas Manion as the Company’s Chief Executive Officer, effective as of January 1, 2023.”
Frank Ruffo retired as other_named_officer at Aclaris Therapeutics, Inc..
“In connection with Mr. Ruffo’s previously announced retirement, on December 9, 2022, Aclaris Therapeutics, Inc. (the “ Company ”) and Mr. Ruffo entered into a Separation Agreement and General Release”
Christopher Molineaux changed role as Lead Independent Director at Aclaris Therapeutics, Inc..
“Christopher Molineaux will assume the role of Lead Independent Director on January 1, 2023.”
Kevin Balthaser was appointed as Chief Financial Officer at Aclaris Therapeutics, Inc..
“the Board appointed Kevin Balthaser as the Company’s Chief Financial Officer, effective as of January 1, 2023.”
Douglas Manion was appointed as Class I Director at Aclaris Therapeutics, Inc..
“The Board also appointed Dr. Manion to the Board to serve as a Class I director to hold office until the 2025 annual meeting of stockholders”
Douglas Manion was appointed as Chief Executive Officer at Aclaris Therapeutics, Inc..
“the Board appointed Douglas Manion, age 62, M.D., FRCP (C), as the Company’s Chief Executive Officer effective January 1, 2023, in addition to his role as President which he has held since August 2022.”
Frank Ruffo retired as Chief Financial Officer at Aclaris Therapeutics, Inc..
“Mr. Ruffo notified the Company that he will retire from his positions as Chief Financial Officer and Corporate Secretary of the Company, effective December 31, 2022.”
Neal Walker was appointed as Chair of the Board at Aclaris Therapeutics, Inc..
“the Board appointed Dr. Walker as the Chair of the Board, effective January 1, 2023.”
Neal Walker resigned as Chief Executive Officer at Aclaris Therapeutics, Inc..
“Dr. Walker notified Aclaris Therapeutics, Inc. (the “ Company ”) that he will resign from his position as Chief Executive Officer of the Company, effective December 31, 2022.”
Aclaris Therapeutics, Inc. reported financial results for the quarter and nine months ended September 30, 2022.
“On November 8, 2022, Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2022”
Neal Walker changed role as President at Aclaris Therapeutics, Inc..
“Neal Walker will no longer serve as the Company’s President, but will continue to serve as the Company’s Chief Executive Officer.”
Douglas Manion was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..
“appointed Douglas Manion, M.D., FRCP (C), as the Company’s President and Chief Operating Officer effective August 1, 2022.”
Kamil Ali-Jackson retired as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary at Aclaris Therapeutics, Inc..
“On November 1, 2021, Ms. Ali-Jackson notified the Company that she will retire from her position as the Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of the Company, effective January 3, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.